Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GR2102
- Development stage
- Phase 1
- Lead developer
- Zhixiang (Shanghai) Medical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Injection
01
Overview
GR2102 is a recombinant all-human monoclonal antibody developed for the prevention of respiratory syncytial virus (RSV) infection. It specifically targets and binds to the Fusion glycoprotein F of respiratory syncytial virus on the surface of RSV, thereby blocking viral entry into host cells and preventing infection. The drug is being independently developed by Genrix Biopharmaceutical (also referred to as Zhixiang Jintai or Zhixiang (Shanghai) Medical Technology), with clinical trials currently underway in China. Its primary indication is for RSV infections, and it is administered via injection. As of now, there are no approved indications or known adverse events reported for this drug.
02
Targets
Beyond the preview
Go deeper on GR2102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GR2102.